Traders should monitor test adoption trends and potential inclusion in broader clinical guidelines; this level of prospective validation may drive increased payer coverage and physician uptake, supporting revenue growth.
Price Chart
Executive Summary
Castle Biosciences announced new prospective, multicenter study data showing that its DecisionDx-Melanoma test, via the i31-SLNB algorithm, accurately identifies melanoma patients with less than 5% predicted risk of sentinel lymph node (SLN) positivity—aligning with NCCN guidelines to forgo SLNB. Patients with low-risk results had only 2.6% actual SLN positivity and 97.8% three-year recurrence-free survival, supporting clinical utility and potential to reduce unnecessary surgeries.
Key Facts
- New data from a prospective, multicenter study of 912 patients shows DecisionDx-Melanoma’s i31-SLNB test accurately stratifies SLN positivity risk.
- Patients with <5% predicted risk had 2.6% actual SLN positivity; in T1b–T2a subgroup, it was just 1.4%.
- High-risk patients (>10% predicted) had 21.4% actual SLN positivity (13.2x higher than low-risk).
- Low-risk patients showed 97.8% three-year recurrence-free survival.
- Study supports test’s ability to reduce unnecessary SLNBs while maintaining strong outcomes.
- Data presented at SSO 2026 and accepted for publication in Future Oncology.
Financial Impact
Potential for increased test adoption and revenue growth as clinical validation strengthens; no direct financial figures provided.
Risk Factors
- Forward-looking statements: actual adoption may not match expectations.
- Reimbursement challenges or payer resistance could limit commercial impact.
- Future studies could contradict current findings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251673 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Insider Cluster | $33.19 $33.08 | ▼ −0.33% | ▲ +0.19% | $33.30 (+0.33%) |
Oct 5, 2026 21d ago | 144 | $33.36 $33.00 | ▼ −1.08% | ▼ −0.84% | $33.30 (−0.18%) |
Oct 5, 2026 21d ago | Insider Cluster | $33.36 $33.00 | ▼ −1.08% | ▼ −0.84% | $33.30 (−0.18%) |
Sep 23, 2026 4w ago | Insider Cluster | $35.19 $35.81 | ▼ −1.76% | ▼ −1.22% | $33.30 (+5.37%) |
Sep 16, 2026 5w ago | Insider Cluster | $36.78 $35.34 | ▼ −3.92% | ▼ −4.04% | $33.30 (−9.46%) |
Sep 11, 2026 6w ago | 144 | $33.44 $35.50 | ▲ +6.16% | ▲ +6.62% | $33.30 (−0.42%) |
Sep 3, 2026 7w ago | Insider Cluster | $32.91 $32.76 | ▲ +0.46% | ▼ −0.09% | $33.30 (−1.19%) |
Sep 2, 2026 7w ago | Insider Cluster | $32.65 $32.91 | ▲ +0.80% | ▲ +1.18% | $33.30 (+1.99%) |
Sep 1, 2026 7w ago | Insider Cluster | $33.42 $32.65 | ▼ −2.30% | ▼ −3.35% | $33.30 (−0.36%) |
Aug 27, 2026 8w ago | Insider Cluster | $33.50 $33.03 | ▼ −1.40% | ▼ −1.10% | $33.30 (−0.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers